RNA Interference based Midkine Gene Therapy for Hepatocellular Carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Hepatocellular carcinoma (HCC) is a primary liver cancer with poor prognosis due to late diagnosis and resistance to conventional therapies.
• Midkine (MDK) is implicated in cancer development and progression.
• Investigating novel therapeutic strategies targeting specific molecular pathways is crucial for improving HCC outcomes.

Purpose of the Study:

• To evaluate Midkine (MDK) serum levels as a diagnostic biomarker for HCC detection.
• To assess the therapeutic potential of RNA interference (RNAi)-mediated MDK silencing in HCC.

Main Methods:

• Serum and tissue samples were collected from 120 HCC patients and 20 healthy controls.
• Midkine (MDK) expression was quantified using ELISA and qRT-PCR.
• In vitro studies utilized MDK-siRNA to assess gene knockdown efficiency and its effect on HepG2 cell proliferation.

Main Results:

• MDK expression was significantly elevated in the serum and tumor tissues of HCC patients compared to controls (P<0.001).
• RNA interference-mediated down-regulation of MDK significantly inhibited HepG2 cell proliferation in vitro.
• Successful gene knockdown of MDK was confirmed by qRT-PCR and ELISA.

Conclusions:

• Elevated MDK levels serve as a potential diagnostic biomarker for HCC.
• Molecular targeting of MDK using RNA interference demonstrates therapeutic potential by reducing HCC cell proliferation.
• MDK represents a promising therapeutic target for hepatocellular carcinoma treatment.